Clinical Trials
51 trialsIs Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Tianjin Medical University Second Hospital
eRapa
The University of Texas Health Science Center at San Antonio
INTerpath-011
Merck Sharp & Dohme LLC
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
BLATAM
SURF302
Tyra Biosciences, Inc
ADVANCED-2
Protara Therapeutics
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
ReplaceCysto
White River Junction Veterans Affairs Medical Center
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Lepu Biopharma Co., Ltd.
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ENHANCE
Hoosier Cancer Research Network
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
BicaBCa
CHU de Quebec-Universite Laval
Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Theralase® Technologies Inc.
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
HGNMIBC
Relmada Therapeutics, Inc.
COBRA
Medical University of Vienna
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Fujian Medical University Union Hospital
CORE-001
CG Oncology, Inc.
BRAVE
University of Alberta
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
POLO
University of Bern
TROJAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Qilu Hospital of Shandong University
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer
West China Hospital
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
RemeGen Co., Ltd.
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
University of Rome Tor Vergata
CheckMate 9UT
Bristol-Myers Squibb
OPTIMA II
UroGen Pharma Ltd.
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Sir Mortimer B. Davis - Jewish General Hospital
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Anchiano Therapeutics Israel Ltd.
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Jiangsu Yahong Meditech Co., Ltd aka Asieris
PREVERT
Institut Paoli-Calmettes
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd.
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
FKD Therapies Oy
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
IPOI vs IPOP
Poitiers University Hospital
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
University of Rome Tor Vergata
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company